Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD). We enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue. We randomly assigned 42 patients in a 2:1 ratio to octreotide LAR depot (up to 40 mg every 28+/-5 days) or placebo for 1 year. The primary end point was percent change in liver volume from baseline to 1 year, measured by MRI. Secondary end points were changes in total kidney volume, GFR, quality of life, safety, vital signs, and clinical laboratory tests. Thirty-four patients had ADPKD, and eight had ADPLD. Liver volume decreased by 4.95%+/-6.77% in the octreotide group but remained practically unchanged (+0.92%+/-8.33%) in the placebo group (P=0.048). Among patients with ADPKD, total kidney volume remained practically unchanged (+0.25%+/-7.53%) in the octreotide group but increased by 8.61%+/-10.07% in the placebo group (P=0.045). Changes in GFR were similar in both groups. Octreotide was well tolerated; treated individuals reported an improved perception of bodily pain and physical activity. In summary, octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationVolume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Self-citationGattone, V. H., Wang, X., Harris, P. C., & Torres, V. E. (2003) · Nature Medicine · doi:10.1038/nm935 · Cited by 670
Self-citationAutosomal dominant polycystic kidney disease: the last 3 years
Torres, V. E., & Harris, P. C. (2009) · Kidney International · doi:10.1038/ki.2009.128 · Cited by 590
Self-citationEffective treatment of an orthologous model of autosomal dominant polycystic kidney disease
Torres, V. E., Wang, X., Qian, Q., Somlo, S., Harris, P. C., & Gattone, V. H. (2004) · Nature Medicine · doi:10.1038/nm1004 · Cited by 482
Self-citationComprehensive Molecular Diagnostics in Autosomal Dominant Polycystic Kidney Disease
Rossetti, S., Consugar, M. B., Chapman, A. B., Torres, V. E., Guay-Woodford, L. M., Grantham, J. J., Bennett, W. M., Meyers, C. M., Walker, D. L., Bae, K., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121387 · Cited by 439
Self-citationKwekkeboom, D. J., Bakker, W. H., Kam, B. L., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 424
Wang, X., Gattone, V., Harris, P. C., & Torres, V. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121090 · Cited by 334
Self-citationBae, K. T., Zhu, F., Chapman, A. B., Torres, V. E., Grantham, J. J., Guay-Woodford, L. M., Baumgarten, D. A., King, B. F., Wetzel, L. H., Kenney, P. J., et al. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00080605 · Cited by 312
Self-citationRossetti, S., Kubly, V. J., Consugar, M. B., Hopp, K., Roy, S., Horsley, S. W., Chauveau, D., Rees, L., Barratt, T. M., van't Hoff, W. G., et al. (2009) · Kidney International · doi:10.1038/ki.2008.686 · Cited by 300
Self-citationMutations in SEC63 cause autosomal dominant polycystic liver disease
Davila, S., Furu, L., Gharavi, A. G., Tian, X., Onoe, T., Qian, Q., Li, A., Cai, Y., Kamath, P. S., King, B. F., et al. (2004) · Nature Genetics · doi:10.1038/ng1357 · Cited by 286
Self-citationMasyuk, T. V., Masyuk, A. I., Torres, V. E., Harris, P. C., & Larusso, N. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.039 · Cited by 283
Self-citationRuggenenti, P., Remuzzi, A., Ondei, P., Fasolini, G., Antiga, L., Ene-Iordache, B., Remuzzi, G., & Epstein, F. H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00395.x · Cited by 270
van Keimpema, L., Nevens, F., Vanslembrouck, R., van Oijen, M. G. H., Hoffmann, A. L., Dekker, H. M., de Man, R. A., & Drenth, J. P. H. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.052 · Cited by 257
The benefit of stereology for quantitative radiology.
Roberts, N., Puddephat, M. J., & McNulty, V (2000) · The British Journal of Radiology · doi:10.1259/bjr.73.871.11089458 · Cited by 248
Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease
Drenth, J. P. H., te Morsche, R. H. M., Smink, R., Bonifacino, J. S., & Jansen, J. B. M. J. (2003) · Nature Genetics · doi:10.1038/ng1104 · Cited by 234
Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients
Qian, Q., Du, H., King, B. F., Kumar, S., Dean, P. G., Cosio, F. G., & Torres, V. E. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050626 · Cited by 204
Self-citationMutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S. (2003) · The American Journal of Human Genetics · doi:10.1086/368295 · Cited by 193
Self-citationAntitumor effects of somatostatin
Pyronnet, S., Bousquet, C., Najib, S., Azar, R., Laklai, H., & Susini, C. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.002 · Cited by 177
Schnelldorfer, T., Torres, V. E., Zakaria, S., Rosen, C. B., & Nagorney, D. M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181ad83dc · Cited by 173
Self-citationFabris, L., Cadamuro, M., Fiorotto, R., Roskams, T., Spirlì, C., Melero, S., Sonzogni, A., Joplin, R., Okolicsànyi, L., & Strazzabosco, M. (2006) · Hepatology · doi:10.1002/hep.21143 · Cited by 158
Gattone, V. H., Maser, R. L., Tian, C., Rosenberg, J. M., & Branden, M. G. (1999) · Developmental Genetics · Cited by 141
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly
Davies, P. H. O., Stewart, S. E., Lancranjan, I., Sheppard, M. C., & Stewart, P. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00389.x · Cited by 137
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
Ho, K., Weissberger, A. J., Marbach, P., & Lazarus, L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-3-173 · Cited by 133
Reynolds, D. M., Falk, C. T., Li, A., King, B. F., Kamath, P. S., Huston, J., Shub, C., Iglesias, D. M., Martín, R. S., Pirson, Y., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/316904 · Cited by 101
Self-citationGong, A., Tietz, P. S., Muff, M. A., Splinter, P. L., Huebert, R. C., Strowski, M. Z., Chen, X., & LaRusso, N. F. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00313.2002 · Cited by 79
Self-citationTietz, P. S., Holman, R. T., Miller, L. J., & LaRusso, N. F. (1995) · Biochemistry · doi:10.1021/bi00047a007 · Cited by 76
Self-citationHanson, D. P., Robb, R. A., Aharon, S., Augustine, K. E., Cameron, B. M., Camp, J. J., Karwoski, R. A., Larson, A. N., Stacy, M. C., & Workman, E. L. (1997) · Journal of Imaging Informatics in Medicine · doi:10.1007/bf03168711 · Cited by 58
Somatostatin analogues reduce liver volume in polycystic liver disease: Figure 1
van Keimpema, L., de Man, R. A., & Drenth, J. P. H. (2008) · Gut · doi:10.1136/gut.2008.155721 · Cited by 52
Effects of long term octreotide on gall stone formation and gall bladder function.
Bigg-Wither, G., Ho, K. K. Y., Grunstein, R. R., Sullivan, C. E., & Doust, B. D. (1992) · BMJ · doi:10.1136/bmj.304.6842.1611 · Cited by 34
Use of Somatostatin Analogues in Obesity
Tzotzas, T., Papazisis, K., Perros, P., & Krassas, G. E. (2008) · Drugs · doi:10.2165/00003495-200868140-00003 · Cited by 30
Cited by
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationBergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationCiliopathies: an expanding disease spectrum
Waters, A. M., & Beales, P. L. (2011) · Pediatric Nephrology · doi:10.1007/s00467-010-1731-7 · Cited by 676
Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Metadata
- Authors
- Hogan, M. C., Masyuk, T. V., Page, L. J., Kubly, V. J., Bergstralh, E. J., Li, X., Kim, B., King, B. F., Glockner, J., Holmes, D. R., Rossetti, S., Harris, P. C., LaRusso, N. F., & Torres, V. E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2010-06
- Volume
- 21
- Issue
- 6
- Pages
- 1052-1061
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2119503391
- Cited by
- 333
- References
- 31
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.